type II collagen fragment
(Synonyms: H2N-Gly-Glu-Pro-Gly-Ile-Ala-Gly-Phe-Lys-Gly-Glu-Gln-Gly-Pro-Lys-OH ) 目录号 : GP10084
Specific for cartilaginous tissues
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Type II collagen is composed of a triple helix of three identical α chains. These molecules associate to form a fibril that is stabilized by intermolecular crosslinks1. Damage to the fibrillar meshwork, made up of primarily type II collagen (z 90–95%), may be a critical event in the pathology of many arthritides, due in part to the very slow rate of collagen turnover within the cartilage2.
Type II collagen and aggrecan (a large, aggregating proteoglycan) are the two major components of the extracellular matrix of cartilage. The collagen, which is present in a fibrillar form, provides tensile strength whereas the aggrecan is responsible for compressive stiffness of cartilage3-5. Early damage to type II collagen is predominantly pericellular/ territorial suggests that in the majority of cases collagen damage was mediated by the chondrocyte.
References:
1.Eyre, D.R. 1987. Collagen cross-linking amino acids. Methods Enzymol. 144:115–139.
2.McAnulty, R.J., and G.J. Laurent. 1990. In vivo measurement of collagen metabolism in cartilage and bone. In Methods in Cartilage Research. A. Maroudas and K. Kuettner, editors. Academic Press Inc., San Diego, CA. 140–142.
3.Kempson, G. 1980. The mechanical properties ofarticular cartilage. In The Joints and Synovial Fluid. Volume 2. L. Sokoloff, editor. Academic Press Inc.,New York. 238-239.
4.Schmidt, M. B., V. C. Mow, L. E. Chun, and D. R. Eyre. 1990. Effects of proteoglycan extraction on the tensile behaviour ofarticular cartilage. J. Orthop. Res. 8:353-363.
5.Poole, A. R. 1993. Cartilage in health and disease. In Arthritis and Allied Conditions: A Textbook of Rheumatology. D. J. McCarty and W. J. Koopman, editors. Lea & Febiger, Philadelphia. 279-333.
| Cas No. | SDF | ||
| 别名 | H2N-Gly-Glu-Pro-Gly-Ile-Ala-Gly-Phe-Lys-Gly-Glu-Gln-Gly-Pro-Lys-OH | ||
| Canonical SMILES | NCC(NC(CCC(O)=O)C(N1CCCC1C(NCC(NC(C(C)CC)C(NC(C)C(NCC(NC(CC2=CC=CC=C2)C(NC(CCCCN)C(NCC(NC(CCC(O)=O)C(NC(CCC(N)=O)C(NCC(N3C(C(NC(CCCCN)C(O)=O)=O)CCC3)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O | ||
| 分子式 | C65H102N18O21 | 分子量 | 1471.61 |
| 溶解度 | ≥ 147.1mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.6795 mL | 3.3976 mL | 6.7953 mL |
| 5 mM | 0.1359 mL | 0.6795 mL | 1.3591 mL |
| 10 mM | 0.068 mL | 0.3398 mL | 0.6795 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。